Venetoclax with decitabine or azacitidine in previously untreated TP53mut acute myeloid leukemia

被引：0
|
作者：
Zacholski, Kyle
Bouligny, Ian Michael
Murray, Graeme
Patel, Tilak
Doyel, Michael
Boron, Josh
Tran, Valerie
Gor, Juhi
Hang, Yiwei
Thuy Ho
Venn, Chad Michael
Alnimer, Yanal Mufeed
Wages, Nolan
Grant, Steven
Maher, Keri Renee
机构：
[1] VCU, Massey Canc Ctr, Richmond, VA USA
[2] VCU, Sch Med, Richmond, VA USA
[3] VCU, Dept Internal Med, Richmond, VA USA
[4] Virginia Commonwealth Univ, Richmond, VA USA
[5] VCU, Dept Biostat, Richmond, VA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
基金：
美国国家卫生研究院;
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e19051
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Venetoclax and azacitidine in untreated patients with therapy-related acute myeloid leukemia, antecedent myelodysplastic syndromes or chronic myelomonocytic leukemia
    Vinod Pullarkat
    Keith W. Pratz
    Hartmut Döhner
    Christian Recher
    Michael J. Thirman
    Courtney D. DiNardo
    Pierre Fenaux
    Andre C. Schuh
    Andrew H. Wei
    Arnaud Pigneux
    Jun-Ho Jang
    Gunnar Juliusson
    Yasushi Miyazaki
    Dominik Selleslag
    Martha L. Arellano
    Chenglong Liu
    Jean A. Ridgeway
    Jalaja Potluri
    Jovita Schuler
    Marina Konopleva
    Blood Cancer Journal, 15 (1)
  • [42] Results of a phase 1 b study of venetoclax plus decitabine or azacitidine in untreated acute myeloid leukemia patients? 65 years ineligible for standard induction therapy.
    Pollyea, Daniel Aaron
    Dinardo, Courtney Denton
    Thirman, Michael J.
    Letai, Anthony
    Wei, Andrew H.
    Jonas, Brian Andrew
    Arellano, Martha Lucia
    Frattini, Mark G.
    Kantarjian, Hagop M.
    Chyla, Brenda
    Zhu, Ming
    Potluri, Jalaja
    Humerickhouse, Rod
    Mabry, Mack H.
    Konopleva, Marina
    Pratz, Keith William
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [43] A Phase III, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination With Azacitidine in Previously Untreated Patients With TP53-Mutant Acute Myeloid Leukemia
    Daver, Naval G.
    Vyas, Paresh
    Xing, Guan
    Renard, Camille
    Bagheri, Taravat
    Curtis, Kelly
    Sallman, David A.
    Wei, Andrew H.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S312 - S312
  • [44] Prognostic Value of CRh in Acute Myeloid Leukemia Treated with Venetoclax and Decitabine
    Siddiqui, Maria
    Maiti, Abhishek
    Daver, Naval
    Kadia, Tapan
    Rausch, Caitlin
    Alvarado, Yesid
    Ohanian, Maro
    Sasaki, Koji
    Short, Nicholas
    Takahashi, Koichi
    Yilmaz, Musa
    Ravandi, Farhad
    Kantarjian, Hagop
    DiNardo, Courtney
    Konopleva, Marina
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S303 - S304
  • [45] Evolution of Genomic Landscape in Acute Myeloid Leukemia after Decitabine and Venetoclax
    Maiti, Abhishek
    DiNardo, Courtney D.
    Daver, Naval
    Kadia, Tapan M.
    Borthakur, Gautam
    Short, Nicholas J.
    Pemmaraju, Naveen
    Ohanian, Maro
    Alvarado, Yesid
    Takahashi, Koichi
    Pierce, Sherry A.
    Patel, Keyur P.
    Jabbour, Elias J.
    Garcia-Manero, Guillermo
    Ravandi, Farhad
    Kantarjian, Hagop
    Konopleva, Marina
    BLOOD, 2021, 138
  • [46] RESULTS OF A PHASE 1B STUDY OF VENETOCLAX PLUS DECITABINE OR AZACITIDINE IN UNTREATED ACUTE MYELOID LEUKEMIA PATIENTS ≥65 YEARS INELIGIBLE FOR STANDARD INDUCTION THERAPY
    Pollyea, D. A.
    Di Nardo, C.
    Thirman, M.
    Letai, A.
    Wei, A.
    Jonas, B. A.
    Arellano, M.
    Frattini, M.
    Kantarjian, H.
    Chyla, B.
    Zhu, M.
    Potluri, J.
    Humerickhouse, R.
    Mabry, M.
    Konopleva, M.
    Pratz, K.
    HAEMATOLOGICA, 2016, 101 : 44 - 44
  • [47] A Phase 3, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination with Azacitidine in Previously Untreated Patients with TP53-Mutant Acute Myeloid Leukemia
    Daver, Naval
    Vyas, Paresh
    Chao, Mark
    Xing, Guan
    Renard, Camille
    Ramsingh, Giri
    Sallman, David A.
    Wei, Andrew H.
    BLOOD, 2021, 138
  • [48] A Phase 3, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination With Azacitidine in Previously Untreated Patients With TP53-Mutant Acute Myeloid Leukemia
    Daver, Naval
    Vyas, Paresh
    Chao, Mark P.
    Xing, Guan
    Renard, Camille
    Ramsingh, Giri
    Sallman, David A.
    Wei, Andrew H.
    AMERICAN JOURNAL OF HEMATOLOGY, 2022, 97 : S5 - S6
  • [49] Outcomes By Best Response with Hypomethylating Agent Plus Venetoclax in Adults with Previously Untreated Acute Myeloid Leukemia
    Volpe, Virginia Olivia
    Jain, Akriti G.
    Chan, Onyee
    Padron, Eric
    Sallman, David A.
    Komrokji, Rami S.
    Lancet, Jeffrey E.
    Sweet, Kendra
    BLOOD, 2021, 138
  • [50] Outcomes by best response with hypomethylating agent plus venetoclax in adults with previously untreated acute myeloid leukemia
    Jain, Akriti G.
    Volpe, Virginia O.
    Wang, Chen
    Ball, Somedeb
    Tobon, Katherine
    Chan, Onyee
    Padron, Eric
    Kuykendall, Andrew
    Lancet, Jeffrey E.
    Komrokji, Rami
    Sallman, David A.
    Sweet, Kendra L.
    ANNALS OF HEMATOLOGY, 2025, 104 (01) : 307 - 315
12345